Oncology Research

 
Stock Quotes for Oncology Research top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Large Growth
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for ziop investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for avto investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for ziop investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Medical Care
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for roix investment picks

 
News Articles for Oncology Research top ^
HACKENSACK, N.J. , July 24, 2014 /PRNewswire/ -- Champions Oncology, Inc. (OTC: CSBR) , engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2014 .
Sign-up for Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2014 investment picks
Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy Increased applications of RheoSwitch ® platform and its unique capabilities into targeted cellular oncology products Phase I trial utilizing Ad-RTS-IL-12 in Glioblastoma Multiforme expected to launch in 2H2014 BOSTON and GERMANTOWN, Md., July 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq:ZIOP) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon Corporation (NYSE:XON) to include chimeric antigen receptor T-cell (CAR-T) therapy.
Sign-up for ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of its convertible senior notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Sign-up for Clovis Oncology to Offer $200 Million of Convertible Senior Notes investment picks
Charleston Area Medical Center (CAMC) and Charleston Radiation Therapy Consultants are working with Alliance Oncology, a division of Alliance HealthCare Services, to establish a department of radiation therapy at the CAMC Cancer Center.
Sign-up for Charleston Area Medical Center and Alliance Oncology Set to Establish a New Radiation Therapy Department at CAMC Cancer Center investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site.
Sign-up for Clovis Oncology Announces First Patient Enrolled in TIGER2 Study investment picks
BOSTON and TOKYO, July 31, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq:ZIOP) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Solasia Pharma K.K. ("Solasia"), a developer of oncology pharmaceuticals in-licensed for commercialization in major markets throughout the world, announced today an amendment and restatement of their License and Collaboration Agreement for darinaparsin (Zinapar™ or ZIO-101) and related organoarsenic molecules.
Sign-up for ZIOPHARM Oncology and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin investment picks
Side-By-Side Genomic Analysis of Patients' Tumor and TumorGraft Mouse Avatars Before and After Treatment Also to be Conducted NEW YORK and HACKENSACK, N.J. , June 17, 2014 /PRNewswire/ -- Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR) , a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer.
Sign-up for Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts' Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the initial purchasers of the previously announced offering of the Company’s 2.50% Convertible Senior Notes due 2021 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to exercise in full their option to purchase an additional $37.5 million aggregate principal amount of the Notes.
Sign-up for Clovis Oncology Announces Exercise in Full by Initial Purchasers of Their Option to Purchase an Additional $37.5 Million Aggregate Principal Amount of the Company’s 2.50% Convertible Senior Notes Due 2021 investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the RUCAPANC (Rucaparib Assessment in BRCA-mutated Pancreatic Cancer) study has commenced with the dosing of the first patient at a U.S. study site.
Sign-up for Clovis Oncology Announces First Patient Enrolled in RUCAPANC Study investment picks
HACKENSACK, N.J. , July 21, 2014 /PRNewswire/ -- Champions Oncology (OTC: CSBR) , a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2014 , on Thursday, July 24, 2014 , after market close.
Sign-up for Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 24 investment picks
Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for its second quarter ended June 30, 2014, and provided an update on the Company’s clinical development programs for the rest of 2014.
Sign-up for Clovis Oncology Announces Second Quarter 2014 Operating Results investment picks
SAN FRANCISCO, Calif., June 26, 2014 (GLOBE NEWSWIRE) -- via PRWEB - CollabRx, Inc. (NASDAQ: CLRX) , a data analytics company and leading provider of expert systems that inform therapeutic decision-making in oncology, and OncoSolutions Cancer Center, a private oncology company based in Singapore, announce a multiyear agreement.
Sign-up for CollabRx and OncoSolutions Cancer Center Partner To Provide Precision Oncology Services investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Oncology Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: On-Premise Software  |  Next: One Equity Partners